Noordzij Marlies, Korevaar Johanna C, Bos Willem J, Boeschoten Elisabeth W, Dekker Friedo W, Bossuyt Patrick M, Krediet Raymond T
Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Nephrol Dial Transplant. 2006 Sep;21(9):2513-20. doi: 10.1093/ndt/gfl257. Epub 2006 Jun 24.
The K/DOQI guideline for bone metabolism and disease in chronic kidney disease is predominantly based on studies in haemodialysis (HD) patients. However, in clinical practice, this guideline is also applied to peritoneal dialysis (PD) patients. To validate the implementation of this guideline in PD patients, we evaluated the associations between plasma concentrations outside the K/DOQI-targets and the risk of cardiovascular morbidity and mortality in incident PD patients compared with HD patients.
In a large prospective multicentre study in the Netherlands (The Netherlands Cooperative Study on the Adequacy of Dialysis, NECOSAD), we included patients starting PD or HD between 1997 and 2004. Relative risk of cardiovascular morbidity and mortality were estimated using time-dependent Cox regression modelling.
We included 586 PD patients with mean age 52 +/- 15 years (66% males) and 1043 HD patients with mean age 63 +/- 14 years (58% males). Cardiovascular disease (CVD) was the reason for hospitalization in 102 PD and 271 HD patients. In HD patients, the relative risk of CVD-related hospitalization increased with elevated plasma calcium concentrations (hazard ratio: 1.4; 95% CI: 1.1-1.9). Cardiovascular mortality was significantly higher for phosphorus concentrations above the K/DOQI-threshold in PD (2.4; 95% CI: 1.3-4.2) and HD patients (1.5; 95% CI: 1.1-2.1), and for elevated Ca x P in PD (2.2; 95% CI: 1.3-3.8) and HD patients (1.5; 95% CI: 1.1-2.1).
Plasma calcium concentrations above the K/DOQI-threshold increase the relative risk of CVD-related hospitalization in HD patients. Associations with cardiovascular mortality were more pronounced. Both in PD and HD patients with elevated plasma phosphorus and Ca x P concentrations, the cardiovascular mortality risk is increased. Therefore, it seems appropriate to adopt the current guideline in PD patients.
慢性肾脏病骨代谢和疾病的K/DOQI指南主要基于对血液透析(HD)患者的研究。然而,在临床实践中,该指南也应用于腹膜透析(PD)患者。为验证该指南在PD患者中的实施情况,我们评估了K/DOQI目标范围外的血浆浓度与新发PD患者心血管发病和死亡风险之间的关联,并与HD患者进行比较。
在荷兰的一项大型前瞻性多中心研究(荷兰透析充分性合作研究,NECOSAD)中,我们纳入了1997年至2004年间开始进行PD或HD治疗的患者。使用时间依赖性Cox回归模型估计心血管发病和死亡的相对风险。
我们纳入了586例平均年龄为52±15岁(66%为男性)的PD患者和1043例平均年龄为63±14岁(58%为男性)的HD患者。心血管疾病(CVD)是102例PD患者和271例HD患者住院的原因。在HD患者中,CVD相关住院的相对风险随血浆钙浓度升高而增加(风险比:1.4;95%置信区间:1.1 - 1.9)。在PD患者(2.4;95%置信区间:1.3 - 4.2)和HD患者(1.5;95%置信区间:1.1 - 2.1)中,血浆磷浓度高于K/DOQI阈值时,心血管死亡率显著更高;在PD患者(2.2;95%置信区间:1.3 - 3.8)和HD患者(1.5;95%置信区间:1.1 - 2.1)中,钙磷乘积升高时,心血管死亡率也显著更高。
血浆钙浓度高于K/DOQI阈值会增加HD患者CVD相关住院的相对风险。与心血管死亡率的关联更为明显。在血浆磷和钙磷乘积浓度升高的PD和HD患者中,心血管死亡风险均增加。因此,在PD患者中采用当前指南似乎是合适的。